Development Center for Biotechnology

National Health Research Institutes

Szu-Liang Lai

Chu-Bin Liao

Chih-Yung Hu

Cheng-Chou Yu

Yen-Yu Wu

Yu-Kai Chen

Chun-Chung Lee

Chiung-Tong Chen

Chao-Yang Huang

Jiann-Shiun Lai

Chuan-Lung Hsu

Chia-Cheng Wu

Chen-Wei Huang

Wei-Ting Sun

Shu-Ping Yeh

Li-Ya Wang

Chien-Tsun Kuan

Chen-Hsuan Ho

Mei-Ling Hou

Yan-Da Lai

Shih-Liang Hsiao

Wen-Bin Ke

Tzu-Yin Lin

Yi-San Tsai

Kao-Jean Huang

Sih-Yu Chen

Yi-Jiue Tsai

Ya-Ting Juan

Juo-Yu Huang

Tzung-Jie Yang

Li-Shuang Ai

Liang-Yu Hsia

Pei-Shan Wu

Ren-Huang Wu

Chen-Jei Hong

Han-Shu Hu

Andrew Yueh

Yu-Hsun Lo

Tzu-chin Wu

Yu-Jung Chen

Jia-ni Tian

Tze-Ping Yang

The present invention relates to a novel antibody, an antigen-binding fragment thereof and the uses of the antibody and fragment, wherein the antibody and the fragment comprise specific complementarity-determining regions (CDRs) and/or specifically bind to human CD73 at specific epitopes.

Anti-CD73 antibodies and use thereof

A humanized anti-neurotensin receptor 1 (NTSR1) antibody or an antigen-binding fragment thereof. Also, a method for treating, prophylactic treating and/or preventing diseases and/or disorders caused by or related to NTSR1 activity and/or signaling, and a method or kit for detecting NTSR1 in a sample.

Humanized anti-human neurotensin receptor 1 antibodies and their uses

An antibody, or an antigen-binding fragment thereof, that binds specifically to human CSF-1R includes a heavy chain variable domain that contains a HCDR1 region having the sequence of SEQ ID NO: 4, a HCDR2 region having the sequence of SEQ ID NO: 5, and a HCDR3 region having the sequence of SEQ ID NO: 6; and a light chain variable domain that contains a LCDR1 region having the sequence of SEQ ID NO: 7, a LCDR2 region having the sequence of SEQ ID NO: 8, and a LCDR3 region having the sequence of SEQ ID NO: 9. The heavy chain variable domain comprises the sequence of SEQ ID NO: 2, and wherein the light chain variable domain comprises the sequence of SEQ ID NO: 3.

Anti-human CSF-1R antibody and uses thereof

A humanized anti-Globo H antibody, or an scFv or Fab fragment thereof, comprising a heavy-chain variable domain having three complementary regions consisting of HCDR1, HCDR2, and HCDR3 and a light-chain variable domain having three complementary regions consisting of LCDR1, LCDR2, and LCDR3, wherein the sequence of HCDR1 is GYISSDQILN (SEQ ID NO:4), the sequence of HCDR2 is RIYPVTGVTQYXHKFVG (SEQ ID NO:5, wherein X is any amino acid), and the sequence of HCDR3 is GETFDS (SEQ ID NO:6), wherein the sequence of LCDR1 is KSNQNLLX'SGNRRYZLV (SEQ ID NO:7, wherein X&#x2032; is F, Y, or W, and Z is C, G, S or T), the sequence of LCDR2 is WASDRSF (SEQ ID NO:8), and the sequence of LCDR3 is QQHLDIPYT (SEQ ID NO:9).

Humanized antibodies against Globo H and uses thereof in cancer treatments

The present invention relates to an antibody or antigen-binding fragment thereof that bind human vascular endothelial growth factor receptor 2 (VEGFR-2). The present invention also relates to a method for inhibiting VEGFR-2-mediated signaling in a subject in need, a method for treating diseases and/or disorders caused by or related to VEGFR-2 activity and/or signaling in a subject afflicted with the diseases and disorders, a method for treating tumor in a subject afflicted with the tumor, a method for inhibiting cell proliferation of endothelial cells in a subject in need, and a method for detecting human vascular endothelial growth factor receptor in a sample.

Anti-VEGFR antibody and uses thereof

Growing community of inventors

Taipei, Taiwan

Szu-Liang Lai